A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans
Julie Delyon, Raphaël Porcher, Maxime Battistella, Nicolás Meyer, H. Adamski, François Bertucci, B. Guillot, Thomas Jouary, M.‐T. Leccia, S. Dalac, Laurent Mortier, Zineb Ghrieb, Laetitia Da Meda, Éric Vicaut, Florence Pédeutour, Samia Mourah, Célèste Lebbé
Topics & Concepts
PazopanibDermatofibrosarcoma protuberansMedicineSoft tissue sarcomaClinical endpointInternal medicineSarcomaOncologyImatinibAdverse effectDermatofibrosarcomaPDGFBTyrosine-kinase inhibitorResponse Evaluation Criteria in Solid TumorsPhases of clinical researchSurgeryClinical trialPathologyPlatelet-derived growth factor receptorCancerGrowth factorReceptorMyeloid leukemiaSunitinibSarcoma Diagnosis and TreatmentCardiac tumors and thrombiVascular Tumors and Angiosarcomas